Top 100 domestic pharmaceutical companies' product R&D rankings announced: Junshi, Hengrui, CanSino...

In recent years, driven by a series of drug administration reforms and the national science and technology innovation strategy, the research and development of innovative drugs has been in full swing, and the investment in research and development has been increasing year by ye.

The last article (Top 100 A-share pharmaceutical companies with R&D investment! 14 companies exceed 1 billion yuan, 90% of pharmaceutical companies have increased R&D investment, Baiji, Hengrui, Fos.

Although many companies do not disclose the amount of R&D investment in specific projects in their annual reports, they can still get a glimpse of the R&D investment of projects that have been disclosed and know a little about the trend of new drug R&.

These ten new drugs have the most R&D investment

According to the statistics of the product R&D details database of listed companies of Yaozhi, these 10 projects have the most cumulative R&D investment:

Data source: Yaozhi's product R&D detailed database of listed companies, announcements of various companies

The first is Junshi Bio's JS001 (toripalimab), which has invested a total of 68 billion yuan as of 202

Toripalimab is a recombinant humanized anti-PD-1 monoclonal antibody injection, which is the first domestically produced monoclonal antibody targeting PD-1 successfully launched in Chi.

Toripalimab, as the first approved domestic PD-1 mAb, has always been the main source of revenue and profit for Junshi B.

Recently, Junshi released the "2022 Prospectus for the Issuance of A Shares by Specific Objects (Review Draft.

Camrelizumab and Toripalizumab are both PD-1 mA.

In the field of anti-tumor, another innovative drug of Hengrui, pyrotinib, is also expensi.

In addition to the tumor field, the new coronary pneumonia vaccine is also a key investment area for pharmaceutical companies in the past two yea.

In fact, CanSino's focus has been on a COVID-19 vaccine since the outbreak of the new crown in early 202 Its adenovirus vector COVID-19 vaccine Ad5-nCoV (trade name "Kwesa") was approved for listing in mainland China with conditions in February 2021, and then expanded to overseas marke.

Biological drugs account for 65%, and the research and development of traditional Chinese medicine has not been "flat"

According to the statistics of drug types, among the 100 products (projects), biological products accounted for more than half, accounting for 65%, and chemical drugs and traditional Chinese medicine accounted for 23% and 12%, respective.

Since the 20th century, with the gradual deepening of people's understanding of genetics, life evolution and biology, biotechnology has continued to break through, and the biopharmaceutical industry has also entered a stage of rapid developme.

In China, before 2015, the research and development of biological drugs was relatively small, and most of them were mainly recombinant proteins and vaccin.

However, after 2015, with the introduction of a series of new drug policies, the influx of overseas capital and the return of a large number of medical talents, domestic biological drug research and development has ushered in a period of vigorous developme.

On the other hand, it is worth noting that the research and development of traditional Chinese medicines and going overseas have never stopped, but the progress has been slow, and it has only improved slightly in the past two yea.

As early as 1998, Tasly planned to launch Compound Danshen Dripping Pills in the United Stat.

According to Tasly's 2018 annual report, the cumulative R&D investment in the FDA project of Compound Danshen Dripping Pills has reached 480 million yu.

The Phase 3 clinical trials of Compound Danshen Dropping Pills for the treatment of angina pectoris and acute altitude sickness are still in progress, and it will take time to answer whether they can go overseas successful.

The progress of innovative traditional Chinese medicine drugs is also slow in China, and very few new drugs are approved every ye.

Fortunately, in the past two years, innovative traditional Chinese medicine has finally improv.

According to the statistics of Yaozhi, a total of 10 new Chinese medicines will be approved for marketing in 2021, 9 of which are Chinese medicine compound prescriptions (8 are clinical experience prescriptions of traditional Chinese medicine, 1 is a basic prescription of hospital preparations), and 1 is an effective part of traditional Chinese medicin.

Only 3 new Chinese medicines have been approved in 2020, and even fewer before th.

The rise of these new brands and new categories adapted to the new era shows that the research and development of new Chinese medicines has been opened up, and the research and development of traditional Chinese medicines has also ushered in a new upsur.

Attached table: TOP 100 investment in product R&D of A-share listed pharmaceutical companies

Note: The cumulative R&D investment of drugs (products)/under-research projects only counts the data disclosed in the annual repo.

If there are any errors or omissions, please correct th.

Data source: Yaozhi's product R&D detailed database of listed companies, announcements of various companies